RALEIGH, N.C., Feb. 27 /CNW/ -- DARA BioSciences(TM) (Nasdaq: DARA)
announced today the appointment of Haywood D. Cochrane, Jr. to the Board of
Directors. Mr. Cochrane was appointed to fill a Board vacancy and will serve
on the Company's Audit and Compensation Committees. The appointment was
effective February 21, 2008.
In making the announcement DARA's Board Chairman, Richard Franco, Sr.,
commented, "We are pleased that Haywood has joined us as a Director. His vast
knowledge and successful experience in the healthcare industry will further
strengthen DARA's already skilled Board."
Mr. Cochrane is currently Vice Chairman and a Director of I-trax, Inc.
(Amex: DMX), a publicly traded, total population health management and
productivity company. Mr. Cochrane has previously served as a Director of
seven other publicly-traded companies.
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based
development-stage pharmaceutical company that acquires promising therapeutic
molecules and medical technologies directly or through investment in
established companies. DARA focuses its therapeutic development efforts on
small molecules from late preclinical development through phase 2 clinical
trials. DARA is developing a portfolio of therapeutic candidates for
neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia
and dermatological disorders. DARA has licensed promising drug development
candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals
Corporation, Massachusetts General Hospital and Nuada LLC.
For more information please contact the Company at 919-872-5578 or visit
our web site at www.darabio.com.
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities Exchange Act
of 1934 as amended. Such forward-looking statements are subject to factors
that could cause actual results to differ materially for DARA from those
projected. Those factors include risks and uncertainties relating to the
company's ability to develop and bring new products to market as anticipated,
the current regulatory environment in which the company develops and sells its
products, the market acceptance of those products, dependence on partner,
successful performance under collaborative and other commercial agreements,
competition, the strength of DARA's intellectual property, the intellectual
property of others and other risk factors identified in the documents DARA has
filed, or will file, with the Securities and Exchange Commission. Copies of
DARA's filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based. DARA BioSciences and the DARA logo are trademarks
of DARA BioSciences, Inc.
For further information:
For further information: John C. Thomas, Jr., Chief Financial Officer,
+1-919-872-5578, or Lynn H. Morris, Sr. Manager, Investor Relations &
Corporate Operations, +1-919-872-5578, both of DARA BioSciences, Inc. Web